ACIP panel may postpone meeting, latest sign of CDC dysfunction
The Department of Health and Human Services has failed to meet the legal deadline for announcing an upcoming meeting of the Advisory Committee on Immunization Practices (ACIP), sparking concerns about a potential postponement. According to federal regulations, agencies must provide notice of advisory committee meetings within a specific timeframe to allow for public input. Both a Federal Register notice and a federal rule updated in 2001 specify different deadlines for posting meeting notices, which the HHS has missed.
The meeting, which was scheduled to address topics related to Covid-19 vaccines and other mRNA-based immunizations, is one of three annual ACIP meetings. The committee is responsible for making recommendations on vaccine usage to the Centers for Disease Control and Prevention (CDC), with final approval required from the CDC director or the HHS secretary.
The lack of organization surrounding the February meeting is seen as a reflection of broader dysfunction within the agency. The recent departure of acting CDC Director Jim O’Neill, followed by a reshuffling at HHS, has raised questions about the agency’s direction. O’Neill’s exit came amid disagreements over vaccination policy, leading to speculation about the appointment of a new acting director.
The uncertainty surrounding the ACIP meeting has also affected CDC employees, with conflicting information about the meeting’s status. Despite internal discussions suggesting a possible postponement, no official decision has been made. The recent restructuring of the ACIP by HHS Secretary Robert F. Kennedy Jr., which included the dismissal of the previous panel and the appointment of new members with vaccine-skeptical views, has further complicated the situation.
The turmoil within the agency has also spilled over into vaccine policy decisions, such as the recent controversy over the FDA’s handling of Moderna’s flu shot application. Despite efforts to shift focus towards more politically popular issues, HHS continues to grapple with vaccine-related challenges. The American Academy of Pediatrics has even requested a delay in the ACIP meeting as part of a larger legal dispute over vaccine policy changes.
As the situation unfolds, it remains unclear whether the ACIP meeting will proceed as planned or face further delays. The agency’s ability to navigate these challenges will be closely watched by public health experts and stakeholders alike.
